Curaleaf (OTCMKTS:CURLF – Get Free Report) was upgraded by research analysts at Cormark from a “hold” rating to a “moderate buy” rating in a research report issued to clients and investors on Monday, Zacks.com reports. Cormark also issued estimates for Curaleaf’s FY2024 earnings at ($0.25) EPS and FY2025 earnings at ($0.18) EPS.
Separately, Needham & Company LLC reiterated a “buy” rating and set a $6.25 price target on shares of Curaleaf in a report on Thursday, August 8th.
Check Out Our Latest Analysis on CURLF
Curaleaf Stock Down 0.5 %
Curaleaf (OTCMKTS:CURLF – Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.01). Curaleaf had a negative return on equity of 14.43% and a negative net margin of 20.29%. The company had revenue of $342.29 million for the quarter, compared to the consensus estimate of $344.57 million. On average, research analysts anticipate that Curaleaf will post -0.21 earnings per share for the current year.
Curaleaf Company Profile
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Read More
- Five stocks we like better than Curaleaf
- What Are the U.K. Market Holidays? How to Invest and Trade
- Buy On Holdings Stock Before the Market Catches Its Second Wind?
- When to Sell a Stock for Profit or Loss
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- What is the S&P/TSX Index?
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.